November 27, 2023
|
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010
|
|
November 14, 2023
|
Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe
|
|
November 2, 2023
|
Outlook Therapeutics® Provides Update on Type A Meetings with FDA
|
|
November 1, 2023
|
Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference
|
|
September 29, 2023
|
Outlook Therapeutics® Requests Type A Meeting With FDA
|
|
September 21, 2023
|
Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
|
|
September 5, 2023
|
Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference
|
|
August 30, 2023
|
Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
|
|
August 14, 2023
|
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
|
|
August 1, 2023
|
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
|
|